Research
Hormonal
PPARα agonists (fibrates) significantly reduce cardiovascular events and myocardial infarction in subjects without existing cardiovascular disease, making them effective for primary prevention.
If you have high triglycerides or dyslipidemia but no heart disease, ask your doctor if a fibrate like fenofibrate or bezafibrate is right for you. Studies show these drugs can significantly reduce your risk of heart attacks and other cardiovascular events, offering protection beyond just lowering cholesterol.
GoodSupportsHIGH confidence
a recent systematic review concluded that fibrates significantly lower CVD events and myocardial infarction by 16% and 21% respectively among subjects without existing CVD issues, strongly pointing out the clinical significance of PPARα agonists as an effective primary preventive therapy against CVD [90].
Why this rating
Supported by a systematic review, indicating robust evidence.
Source
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Hong Sheng Cheng et al. · International Journal of Molecular Sciences · 2019
DOI 10.3390/ijms20205055
narrative_reviewCited 257×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dual-PPARα/γ agonists (glitazars) like muraglitazar, tesaglitazar, and aleglitazar have largely failed in clinical development for type 2 diabetes and cardiovascular disease due to severe safety concerns, including heart failure, renal dysfunction, and increased mortality.Strong
- PPARγ agonist pioglitazone significantly reduces the risk of major cardiovascular events (stroke and myocardial infarction) in patients with type 2 diabetes and high cardiovascular risk, including those with prediabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →